Issues and Updates in Hereditary Angioedema
Allergy/ Immunology
Curriculum:
Issues and Updates in Hereditary Angioedema
Issues and Updates in Hereditary Angioedema
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 27, 2017
December 27, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Allergy/immunology physicians, allergy/immunology NPs and PAs, dermatology physicians, dermatology NPs and PAs
Relevant Terms:
Hereditary Angioedema
Marc Riedl, MD, MS
Marc Riedl, MD, MS
Professor of Medicine
Clinical Director, US HAEA Angioedema Center
Division of Rheumatology, Allergy and Immunology
University of California, San Diego
San Diego, CA
Bio
Marc Riedl, MD, MS, is professor of medicine at the University of California, San Diego (UCSD), and clinical director at the US HAEA Angioedema Center at UCSD in San Diego, CA. He received his medical degree from the University of Chicago–Pritzker School of Medicine, and completed a residency in internal medicine at Barnes-Jewish Hospital of Washington University in St. Louis, MO and a fellowship in clinical immunology and allergy at the University of California, Los Angeles (UCLA). Dr Riedl received a Master of Science degree in clinical research and completed advanced training in clinical pharmacology at UCLA. He is board certified in internal medicine, clinical pharmacology, and allergy and immunology.
Dr Riedl's professional interests include angioedema conditions and primary immunodeficiencies. He has published extensively in these areas, serves on numerous editorial boards and scientific committees, as well as appointed expert panels for the Food and Drug Administration and National Institutes of Health, and directs an active clinical research program at UCSD.
Dr Riedl's professional interests include angioedema conditions and primary immunodeficiencies. He has published extensively in these areas, serves on numerous editorial boards and scientific committees, as well as appointed expert panels for the Food and Drug Administration and National Institutes of Health, and directs an active clinical research program at UCSD.
Michael E. Manning, MD, FAAAAI, FACAAI
Michael E. Manning, MD, FAAAAI, FACAAI
President / Medical Director
Medical Research of Arizona
Allergy, Asthma & Immunology Associates, Ltd.
Scottsdale, AZ
Bio
Michael E. Manning, MD, FAAAAI, FACAAI, is president of Allergy, Asthma and Immunology Associates, Ltd., and medical director of the clinical research division, Medical Research of Arizona.
Dr Manning is a graduate of Baylor University in Waco, TX, and he received his medical degree from the University of Texas Medical School at Houston. He completed an internship and subsequent residency in internal medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ, and an allergy and immunology fellowship at Scripps Clinic and Research Foundation in La Jolla, CA.
Dr Manning has served as president of the Greater Phoenix Allergy Society, the Arizona State Allergy and Asthma Society, and the Western Society of Allergy, Asthma and Immunology. He is a fellow of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. Dr Manning is currently on the Board of Regents of the American College of Allergy, Asthma and Immunology.
Dr Manning is a graduate of Baylor University in Waco, TX, and he received his medical degree from the University of Texas Medical School at Houston. He completed an internship and subsequent residency in internal medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ, and an allergy and immunology fellowship at Scripps Clinic and Research Foundation in La Jolla, CA.
Dr Manning has served as president of the Greater Phoenix Allergy Society, the Arizona State Allergy and Asthma Society, and the Western Society of Allergy, Asthma and Immunology. He is a fellow of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. Dr Manning is currently on the Board of Regents of the American College of Allergy, Asthma and Immunology.
Daniel F. Soteres, MD, MPH
Daniel F. Soteres, MD, MPH
Clinical Professor
University of Colorado Health Sciences Center
Denver, CO
Bio
Daniel F. Soteres, MD, MPH, received his medical degree from Tulane University School of Medicine in New Orleans while simultaneously earning a master’s degree in public health. He completed a 4-year combined residency in internal medicine and pediatrics and was a chief resident in internal medicine. After completing his allergy and immunology fellowship at Tulane, Dr Soteres became board-certified in allergy and immunology.
Dr Soteres is an associate clinical professor on faculty at the University of Colorado Health Sciences Center in Denver, CO. He has been in practice at the Asthma and Allergy Associates and Research Center since 2005. In addition to clinical practice, Dr Soteres is the past president of the Colorado Allergy Asthma Society.
Dr Soteres’ interests in the medical field range from the joy of clinical practice and taking care of patients to the challenges and academic rigor associated with research. He also believes in the importance of community service and has many volunteer commitments.
| 1. | Recognize the possibility of hereditary angioedema (HAE) in patients who present with angioedema and integrate a diagnostic workup for angioedema that includes analysis for the various types of HAE (Type I, Type II, and normal C1-INH) | 2. | Incorporate current, novel, and emerging treatments for HAE based on an understanding of their efficacy, safety, and guidance for use |
| 1. | Recognize the possibility of hereditary angioedema (HAE) in patients who present with angioedema and integrate a diagnostic workup for angioedema that includes analysis for the various types of HAE (Type I, Type II, and normal C1-INH) |
| 2. | Incorporate current, novel, and emerging treatments for HAE based on an understanding of their efficacy, safety, and guidance for use |
PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, San Diego School of Medicine and RMEI Medical Education, LLC. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of California, San Diego School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Cultural Competency
This activity is in compliance with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum in the subjects of cultural and linguistic competencies. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables healthcare professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and Linguistic Competency was incorporated into the planning of this activity. Additional resources on cultural and linguistic competency and information about AB1195 can be found on the UC San Diego CME website at http://cme.ucsd.edu.
DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/ or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Marc A. Riedl, MD, MS, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Ionis, Pharming, Shire (Research); Adverum, Alnylam, BioCryst, CSL Behring, KalVista, Pharming, Shire, (Consulting Fees)
- Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, Dyax, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Dyax, Pharming, Shire (Research); CSL Behring, Pharming, Shire (Advisory Board); CSL Behring (Consulting Fees)
- Daniel F. Soteres, MD, MPH, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); CSL Behring, Shire (Research); CSL Behring, Shire (Advisory Board); CSL Behring, Pharming, Shire (Consulting Fees)
The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Estimated time to complete: 1.0 hour
Medium: Internet
FEE INFORMATION
There is no fee for this educational activity.
COMMERCIAL SUPPORT
The activity is supported in part by educational grants from CSL Behring, Pharming Healthcare, Inc., and Shire.
HOW TO RECEIVE CREDIT
The estimated time to complete this activity is 1 hour. To obtain credit, participants should view the presentation, answer the multiple-choice post-test questions, and complete the evaluation form online to receive a certificate.
Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
